DYN Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of --. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat CEL-SCI Corp.'s return on equity of -266.61%.

Dyne Therapeutics, Inc. has a consensus price target of $35.38, signalling upside risk potential of 71.31%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 575.68%. Given that CEL-SCI Corp. has higher upside potential than Dyne Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Dyne Therapeutics, Inc..

Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Dyne Therapeutics, Inc.'s net income of -$108M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -953.4%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Dyne Therapeutics, Inc. has a consensus price target of $35.38, signalling upside risk potential of 71.31%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1125.09%. Given that IGC Pharma, Inc. has higher upside potential than Dyne Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Dyne Therapeutics, Inc..

Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Dyne Therapeutics, Inc.'s net income of -$108M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 22.97x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -255.85%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Dyne Therapeutics, Inc. has a consensus price target of $35.38, signalling upside risk potential of 71.31%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Dyne Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Dyne Therapeutics, Inc.'s net income of -$108M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -1398.33%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Avidity Biosciences, Inc.'s return on equity of -37.47%.

Dyne Therapeutics, Inc. has a consensus price target of $35.38, signalling upside risk potential of 71.31%. On the other hand Avidity Biosciences, Inc. has an analysts' consensus of $74.00 which suggests that it could grow by 3.44%. Given that Dyne Therapeutics, Inc. has higher upside potential than Avidity Biosciences, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Avidity Biosciences, Inc..

Dyne Therapeutics, Inc. has a beta of 1.302, which suggesting that the stock is 30.242% more volatile than S&P 500. In comparison Avidity Biosciences, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.581%.

Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Avidity Biosciences, Inc. pays out -- of its earnings as a dividend.

Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Avidity Biosciences, Inc. quarterly revenues of $12.5M. Dyne Therapeutics, Inc.'s net income of -$108M is higher than Avidity Biosciences, Inc.'s net income of -$174.4M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Avidity Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 450.16x for Avidity Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.